MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...
ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy
Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...
Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...
Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting
The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...
United Family Healthcare Partners with HSS for Orthopedic Collaboration
United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...
MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China
Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma
China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program
China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...
Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA
Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...